These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542 [TBL] [Abstract][Full Text] [Related]
10. The eIg technology to generate Ig-like bispecific antibodies. Kühl L; Aschmoneit N; Kontermann RE; Seifert O MAbs; 2022; 14(1):2063043. PubMed ID: 35427197 [TBL] [Abstract][Full Text] [Related]
11. Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy. Fujisawa S; Konnai S; Okagawa T; Maekawa N; Tanaka A; Suzuki Y; Murata S; Ohashi K BMC Vet Res; 2019 Feb; 15(1):68. PubMed ID: 30819151 [TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. Steeland S; Puimège L; Vandenbroucke RE; Van Hauwermeiren F; Haustraete J; Devoogdt N; Hulpiau P; Leroux-Roels G; Laukens D; Meuleman P; De Vos M; Libert C J Biol Chem; 2015 Feb; 290(7):4022-37. PubMed ID: 25538244 [TBL] [Abstract][Full Text] [Related]
13. Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin. Pleckaityte M; Zvirbliene A; Sezaite I; Gedvilaite A Microb Cell Fact; 2011 Dec; 10():109. PubMed ID: 22171920 [TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of TNFR1 reduces osteoclast numbers and is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss. Espirito Santo AI; Ersek A; Freidin A; Feldmann M; Stoop AA; Horwood NJ Biochem Biophys Res Commun; 2015 Sep; 464(4):1145-1150. PubMed ID: 26208457 [TBL] [Abstract][Full Text] [Related]
16. Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning. Abe Y; Yoshikawa T; Inoue M; Nomura T; Furuya T; Yamashita T; Nagano K; Nabeshi H; Yoshioka Y; Mukai Y; Nakagawa S; Kamada H; Tsutsumi Y; Tsunoda S Biomaterials; 2011 Aug; 32(23):5498-504. PubMed ID: 21546081 [TBL] [Abstract][Full Text] [Related]
17. The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. Richter F; Williams SK; John K; Huber C; Vaslin C; Zanker H; Fairless R; Pichi K; Marhenke S; Vogel A; Dhaen MA; Herrmann S; Herrmann A; Pfizenmaier K; Bantel H; Diem R; Kontermann RE; Fischer R Front Immunol; 2021; 12():705485. PubMed ID: 34305946 [TBL] [Abstract][Full Text] [Related]
18. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency. Scallon B; Cai A; Radewonuk J; Naso M Mol Immunol; 2004 May; 41(1):73-80. PubMed ID: 15140577 [TBL] [Abstract][Full Text] [Related]
19. TNF receptor II fusion protein with tandemly repeated Fc domains. Nagashima H; Kaneko K; Yamanoi A; Motoi S; Konakahara S; Kohroki J; Masuho Y J Biochem; 2011 Mar; 149(3):337-46. PubMed ID: 21278157 [TBL] [Abstract][Full Text] [Related]
20. Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity. Ji X; Lu W; Zhou H; Han D; Yang L; Wu H; Li J; Liu H; Zhang J; Cao P; Zhang S Appl Microbiol Biotechnol; 2013 Oct; 97(19):8547-58. PubMed ID: 23324801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]